UCB Cancels Sale of Generic-Drug Unit to Buyout Firms

Updated on

UCB SA’s sale of its U.S. generic-drug business to two private-equity firms for $1.53 billion fell apart after U.S. regulators asked for an additional study on one of the unit’s products.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.